A5034380203- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Thyroid Disorders and Treatments
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Brain Metastases and Treatment
- RNA modifications and cancer
- Long-Term Effects of COVID-19
- COVID-19 Clinical Research Studies
Humanitas University
2022-2024
IRCCS Humanitas Research Hospital
2023-2024
Institut Gustave Roussy
2024
Aims: This retrospective study aims to identify a possible predictive role of KRAS mutations in non-small-cell lung cancer response first-line pembrolizumab, either as monotherapy or combined with chemotherapy. Methods: Patients received pembrolizumab alone (n = 213) associated chemotherapy 81). Results: A mutation the gene was detected 27% patients. In patients on alone, median progression-free survival KRAS-mutated cases longer than wild-type (11.3 vs 4.4 months; p 0.019), whereas overall...
Small-cell lung cancer is an extremely chemo-sensitive disease; the addition of immunotherapy to chemotherapy has demonstrated a slight clinical benefit in pivotal trials, even with statistically significant difference terms survival outcomes when compared alone. In this scenario, role radiotherapy as consolidation treatment thoracic disease or prophylactic therapy brain should be clarified. addition, due frailty and poor prognostic characteristics these patients, need for predictive...
Abstract INTRODUCTION: Liquid biopsy (LB) proved its clinical utility in advanced non-small cell lung cancer, but role early-stage disease is less clear. Here, we investigated the of LB for molecular diagnosis cancer and correlation with relapse. METHODS: This retrospective, monocentric study collected results from performed patients (pts) an between January 2021 May 2023, within prospective STING (NCT04932525). LBs were executed at different time points (before, after curative treatment, or...
Abstract Background: RET fusions can be found in 1-2% of patients (pts) with advanced non-small cell lung cancer (aNSCLC). While targeted treatment inhibitors (RETi) has significantly improved prognosis, resistance eventually develops. Current knowledge regarding the pattern disease progression and optimal therapeutic sequence for treated RETi is limited. Methods: We conducted a retrospective multicentric collection clinical biological data on pts RET-rearranged (RET+) aNSCLC...
Oncogene-addicted non-small cell lung cancer (NSCLC) patients present a high incidence of CNS metastases either at diagnosis or during the course disease. In this case, with worse prognosis and are often excluded from clinical trials unless brain pre-treated clinically stable.As result discovery several oncogenic drivers in ALK/ROS1/NTRK-positive NSCLC, targeted agents have been tested trials. We evaluate compare intracranial efficacy available NSCLC based on subgroup analysis pivotal...